On Tuesday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened higher 29.93% from the last session, before settling in for the closing price of $1.37. Price fluctuations for ZNTL have ranged from $1.01 to $3.32 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -12.89% annually for the last half of the decade. Company’s average yearly earnings per share was noted 21.73% at the time writing. With a float of $55.15 million, this company’s outstanding shares have now reached $72.25 million.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 23.67%, while institutional ownership is 56.10%. The most recent insider transaction that took place on Dec 15 ’25, was worth 9,975,000. In this transaction 10% Owner of this company sold 7,500,000 shares at a rate of $1.33, taking the stock ownership to the 6,459,973 shares. Before that another transaction happened on Apr 30 ’25, when Company’s Director bought 21,000 for $1.40, making the entire transaction worth $29,373. This insider now owns 281,192 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.61 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.68) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.41% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.69 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Let’s dig in a bit further. During the last 5-days, its volume was 2.24 million. That was inferior than the volume of 3.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.48%.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 67.78%, which indicates a significant increase from 65.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1035 in the past 14 days, which was lower than the 0.1037 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4065, while its 200-day Moving Average is $1.4404. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $2.0833. Second resistance stands at $2.3867. The third major resistance level sits at $2.7433. If the price goes on to break the first support level at $1.4233, it is likely to go to the next support level at $1.0667. Assuming the price breaks the second support level, the third support level stands at $0.7633.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 72,251K shares outstanding in the company with a market cap of 128.60 million. Presently, the company’s annual sales total 67,430 K according to its annual income of -165,840 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -26,690 K.
